Rpi-856 A
Rpi-856 A is a competitive inhibitor of HIV-1 protease and HTLV-I protease, with an IC50 of 37 nM against HIV-1 protease and an IC50 of 27 nM against HTLV-I protease. Rpi-856 A inhibits Pepsin with an IC50 of 1.9 μM. Rpi-856 A does not inhibit chymosin, trypsin, chymotrypsin, papain, bromelain, thermolysin, prolyl endopeptidase, carboxypeptidase A or carboxypeptidase B. Rpi-856 A can be used in the research of acquired immunodeficiency syndrome (AIDS) and related diseases, as well as HIV infection.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 157381-54-9
- 分子式: C43H61N7O13
- 分子量:883.98
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
体外実験
Rpi-856 A (3 h) competitively inhibits recombinant HIV-1 protease (expressed in Escherichia coli MM294 (DE3)/pHIV7004), with a Ki of 13 nM and an IC50 of 37 nM[1].
Rpi-856 A (3 h) competitively inhibits recombinant HTLV-I protease (expressed in Escherichia coli MM294 (DE3)/pHTI7707) with an IC50 of 27 nM[1].
Rpi-856 potently inhibits HIV-1 protease in cell-free biochemical assays, with an IC50 value of 37 nM[2].
Rpi-856 A inhibits porcine pepsin with an IC50 of 1.9 μM, and its activity is weaker than that against retroviral protease[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
化学情報
-
CAS 番号 157381-54-9
-
分子量 883.98
-
分子式 C43H61N7O13
-
配列
Val-{Gly(2-(3,5-dihydroxyphenyl))}-Leu-{2-oxo-4-phenyl-3-aminobutanoyl}-Val-Val-Asp
-
シーケンスの短縮
V-{Gly(2-(3,5-dihydroxyphenyl))}-L-{2-oxo-4-phenyl-3-aminobutanoic acid}-VVD
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Rpi-856 A 関連分類
HY-P1981 関連分類
Powered by Bioz